Non-invasive Biomarker Discovery for Pre-cervical or/and Cervical Cancer-HPV DNA and Other Biomarkers in Urine

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The goal of this clinical trial is 1. To test the sensitivity and specificity of using HPV DNA from urine for the detection of pre-cervical or/and cervical cancer. 2. If HPV DNA is not a promising biomarker, other biomarkers will be explored. 3. To develop an effective and non-invasive detection method of the pre-cervical or/and cervical cancer. in Women with menstruation. The main question it aims to answer is: To validate whether HPV DNA from urine could be used as a non-invasive means for the detection of pre-cervical or cervical cancer Participants will 1. Join the briefing session of the study 2. Sign the consent form and health questionnaire 3. Submit the cervical medical report(s) within 3 months or perform sponsored pap smear test 4. Collect the urine sample If there is a comparison group: Researchers will compare The diseased group and the healthy group according to the medical reports they provided to see if HPV DNA from urine is a promising biomarker for the detection of pre-cervical or cervical cancer

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: t
View:

• Female aged between 18 to 65

• Have menstruation

• Had sex before

• Can read and write Chinese/ English

• Without taking any medication (Except nutritional supplements, traditional Chinese medicine, and health care products etc.)

Locations
Other Locations
Hong Kong Special Administrative Region
WomenX Biotech Limited
RECRUITING
Hong Kong
Time Frame
Start Date: 2023-07-20
Estimated Completion Date: 2025-06
Participants
Target number of participants: 300
Treatments
Experimental: Collect HPV DNA from urine
Related Therapeutic Areas
Sponsors
Collaborators: Hong Kong Science and Technology Parks Corporation
Leads: WomenX Biotech Limited

This content was sourced from clinicaltrials.gov